Financial Performance - The company's operating revenue for Q1 2023 was CNY 357,819,300.48, representing a decrease of 7.72% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 30,338,975.13, down 14.67% year-on-year[5]. - Total revenue for Q1 2023 was CNY 357,819,300.48, a decrease of 7.7% compared to CNY 387,754,555.29 in Q1 2022[17]. - Operating income for Q1 2023 was CNY 15,159,094.82, compared to CNY 7,450,836.83 in Q1 2022, indicating an increase of 102.4%[17]. - In Q1 2023, the company's net profit was CNY 25,115,818.28, a decrease of 21.5% compared to CNY 31,978,308.44 in Q1 2022[18]. - The total profit for Q1 2023 was CNY 34,425,573.09, down from CNY 38,877,102.89 in the same period last year, reflecting a decline of 11.8%[18]. - Operating profit for Q1 2023 was CNY 26,415,257.01, compared to CNY 38,787,492.82 in Q1 2022, indicating a decrease of 31.9%[18]. Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 8,609,087.18, a decline of 136.01% compared to the previous year, primarily due to reduced cash recovery from project payments[7]. - Cash flow from operating activities in Q1 2023 was negative at CNY -8,609,087.18, a significant decline from CNY 23,905,233.68 in Q1 2022[20]. - Cash flow from investing activities showed a net outflow of CNY -17,309,858.90 in Q1 2023, compared to CNY -40,457,261.85 in Q1 2022[21]. - The company reported cash and cash equivalents at the end of Q1 2023 amounting to CNY 766,853,465.58, down from CNY 838,751,337.79 at the end of Q1 2022[21]. - The company received CNY 444,243,503.62 in cash from sales of goods and services in Q1 2023, a decrease of 16.1% from CNY 529,403,055.64 in Q1 2022[20]. - Total cash inflow from investment activities in Q1 2023 was CNY 13,001,654.99, significantly lower than CNY 51,653,888.09 in Q1 2022[21]. - The company incurred a total cash outflow of CNY 76,146,470.25 from financing activities in Q1 2023, compared to CNY 67,264,784.46 in Q1 2022[21]. Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 6,520,649,223.69, a decrease of 2.63% from the end of the previous year[6]. - Total assets as of Q1 2023 amounted to CNY 6,520,649,223.69, a decrease from CNY 6,696,905,336.93 at the end of Q1 2022[16]. - Total liabilities for Q1 2023 were CNY 3,092,312,808.40, down from CNY 3,294,827,608.70 in Q1 2022, reflecting a reduction of 6.1%[15]. - The company's cash and cash equivalents decreased to CNY 1,896,861,749.08 in Q1 2023 from CNY 2,070,203,687.09 in Q1 2022[15]. - The company reported a decrease in accounts payable to CNY 465,783,583.26 in Q1 2023 from CNY 589,958,020.53 in Q1 2022, a decline of 21.1%[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,910[9]. - The largest shareholder, Haining Water Investment Group Co., Ltd., held 389,756,986 shares, accounting for 44.98% of total shares[10]. Research and Development - Research and development expenses for Q1 2023 were CNY 6,814,606.71, slightly up from CNY 6,774,895.77 in Q1 2022[17]. - The company did not report any new product developments or market expansion strategies during this quarter[12]. Mergers and Acquisitions - There were no significant mergers or acquisitions reported in the current quarter[12]. Earnings Per Share - Basic and diluted earnings per share remained stable at CNY 0.04 for both Q1 2023 and Q1 2022[19]. Non-Recurring Gains and Losses - The company reported non-recurring gains and losses totaling CNY 6,397,492.69 for the period[7]. Return on Equity - The weighted average return on equity was 1.00%, a decrease of 0.23 percentage points compared to the previous year[6].

Financial Performance - The company's operating revenue for Q3 2022 was approximately ¥464.96 million, a 4.00% increase compared to ¥447.07 million in the same period last year[6]. - Net profit attributable to shareholders for Q3 2022 reached ¥50.92 million, representing a significant increase of 34.21% from ¥37.94 million in the previous year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥50.28 million, a remarkable increase of 988.51% compared to a loss of ¥5.66 million in the same period last year[9]. - The company reported a basic earnings per share of ¥0.14 for Q3 2022, compared to ¥0.06 in the same period last year, marking a 133.33% increase[7]. - The company’s net profit attributable to shareholders for the year-to-date period increased by 42.04% to ¥129.97 million from ¥91.50 million in the previous year[9]. - Net profit for the third quarter of 2022 was ¥121,892,457.90, up from ¥98,476,192.99 in the same quarter of 2021, reflecting a growth of approximately 23.93%[19]. - Earnings per share for the third quarter of 2022 were ¥0.15, compared to ¥0.14 in the same quarter of 2021, showing an increase of about 7.14%[20]. - The total comprehensive income for the third quarter of 2022 was ¥121,892,457.90, compared to ¥104,150,229.27 in the same quarter of 2021, indicating an increase of approximately 16.25%[20]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥177.15 million, an increase of 85.67% compared to ¥95.41 million in the previous year[9]. - The company's cash and cash equivalents amounted to ¥986,788,855.42 as of September 30, 2022, an increase from ¥918,789,028.55 at the end of 2021[14]. - Total cash and cash equivalents at the end of the period reached CNY 951,721,774.50, up from CNY 510,294,771.71 at the end of the previous year[23]. - Cash received from operating activities totaled CNY 1,637,981,920.72, an increase from CNY 1,496,329,191.07 year-over-year[22]. - Cash received from sales of goods and services in the first three quarters of 2022 was ¥1,474,576,820.80, compared to ¥1,411,263,776.20 in 2021, marking an increase of approximately 4.48%[21]. - Cash paid for purchasing goods and services was CNY 1,007,992,406.06, slightly up from CNY 995,873,179.23 in the previous year[22]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥6.60 billion, reflecting a 1.65% increase from ¥6.49 billion at the end of the previous year[7]. - The total liabilities as of the end of the third quarter of 2022 amounted to ¥3,252,145,844.12, compared to ¥3,186,065,352.21 at the end of 2021, representing an increase of approximately 2.07%[17]. - The total equity attributable to shareholders of the parent company was ¥2,936,311,914.23, up from ¥2,893,001,169.07 in the previous year, indicating a growth of about 1.49%[17]. - Total assets reached ¥6,596,915,985.61, up from ¥6,490,151,612.40 at the end of 2021[15]. - Accounts receivable decreased to ¥705,026,730.93 from ¥795,361,157.59 year-over-year[14]. - Inventory increased to ¥166,369,545.95 from ¥111,702,002.51 year-over-year[15]. - Short-term borrowings decreased significantly to ¥178,260,348.00 from ¥410,221,593.80[15]. Investments and Growth - The company completed a merger with Zhejiang Haiyun Environmental Protection Co., Ltd. in December 2021, which has been reflected in the financial statements[8]. - The company expects continued growth in its bioproducts segment, contributing to increased profitability in the upcoming quarters[9]. - The company has ongoing investments in new technologies and market expansion strategies, although specific figures were not disclosed in the report[13]. - Research and development expenses for the first three quarters of 2022 were ¥22,459,678.91, slightly down from ¥24,101,074.95 in 2021, reflecting a decrease of about 6.81%[18]. - The company reported investment income of ¥40,148,523.69 in the third quarter of 2022, a significant increase from ¥338,287.36 in the same quarter of 2021[19]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 26,598[11]. - The largest shareholder, Haining Water Investment Group, holds 389,756,986 shares, representing 44.98% of total shares[11].

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 879,376,842.75, representing a 2.70% increase compared to CNY 856,275,928.72 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was CNY 79,054,003.85, a significant increase of 47.58% from CNY 53,567,105.00 in the previous year[19]. - The net cash flow from operating activities reached CNY 46,030,589.60, marking a substantial increase of 97.02% compared to CNY 23,363,583.29 in the same period last year[19]. - Basic earnings per share (EPS) for the reporting period was ¥0.09, up 12.50% from ¥0.08 in the same period last year[20]. - The diluted EPS also stood at ¥0.09, reflecting the same 12.50% increase compared to the previous year[20]. - The net profit attributable to shareholders for the reporting period reached ¥79,054,003.85, an increase of 47.58% compared to ¥53,567,105.00 in the same period last year, primarily due to increased profits from the bioproducts business and investment income[20]. - The net cash flow from operating activities was ¥46,030,589.60, representing a 97.02% increase from ¥23,363,583.29 in the same period last year, mainly due to increased tax refunds received by companies like Guangyao Thermal Power[20]. Assets and Liabilities - Total assets as of the end of the reporting period amounted to CNY 6,674,227,734.15, reflecting a 2.84% increase from CNY 6,490,151,612.40 at the end of the previous year[19]. - The total liabilities decreased from CNY 3,186,065,352.21 to CNY 3,381,435,722.84, indicating a rise of approximately 6.13%[184]. - The total current assets as of June 30, 2022, amounted to CNY 2,240,979,324.84, an increase from CNY 2,064,071,703.42 at the beginning of the period, reflecting a growth of approximately 8.56%[182]. - The company's long-term borrowings rose from CNY 1,291,967,657.32 to CNY 1,362,692,995.05, an increase of about 5.5%[184]. - The total equity attributable to shareholders decreased slightly from CNY 2,893,001,169.07 to CNY 2,885,396,596.32, a decline of about 0.26%[184]. Operational Highlights - The company completed a major asset restructuring in 2021, acquiring 51% of Haiyun Environmental Protection and other stakes, which has been reflected in the financial statements[21]. - The main business areas include environmental comprehensive governance, biomanufacturing, and thermal power, with a focus on wastewater treatment and solid waste disposal[25][26]. - The company employs an integrated production and operation model for bioproducts, focusing on research, production, supply, and sales[36][37]. - The thermal power business is operated by a subsidiary, producing steam and providing centralized heating primarily to the company and local enterprises[39]. - The company processes externally sourced natural gas into electricity and steam, selling the surplus through pipelines after meeting internal needs[40]. Environmental Compliance - The company is classified as a key pollutant discharge unit in multiple environmental categories, including air and water[97]. - Specific pollutant discharge standards were met, with no exceedances reported for particulate matter and non-methane total hydrocarbons[98]. - The company has established a standardized hazardous waste storage facility, ensuring compliance with environmental management requirements[100]. - The company has achieved compliance with environmental management requirements, passing environmental acceptance and inspections for its discharge outlets[102]. - The company has implemented strict control measures for the discharge of toxic and harmful substances, reporting emissions to the ecological environment authorities annually[110]. Risk Management - The management has highlighted potential risks in the "Management Discussion and Analysis" section of the report[7]. - The company faces risks from rising raw material prices, which could increase production costs and reduce profitability[82]. - Environmental compliance risks are heightened due to stricter regulations, potentially increasing costs for environmental management and compliance[83]. - The company is managing risks related to accounts receivable and cash flow, particularly from clients with tight budgets, which could impact financial stability[85]. - The company has implemented measures to enhance accounts receivable management to maintain asset liquidity[86]. Shareholder Commitments - Haining Water Group and Yunnan Water committed to a net profit of no less than RMB 115 million, RMB 127 million, and RMB 142 million for the years 2021, 2022, and 2023 respectively, after deducting non-recurring gains and losses[140]. - If the actual net profit falls below the committed amount, Haining Water Group and Yunnan Water will compensate the difference in shares and/or cash[140]. - The commitments made by Haining Water Group and Yunnan Water are valid for the years 2021, 2022, and 2023[140]. - Haining Water Group will prioritize compensation with shares it holds, and if insufficient, will cover the shortfall in cash within 10 days[142]. Management Changes - The company underwent a significant management reshuffle, with multiple new appointments including the election of a new chairman and several directors[92]. - The management changes were publicly disclosed in announcements made on May 31, 2022[93].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 387,754,555.29, representing a year-on-year increase of 17.25%[5] - The net profit attributable to shareholders was CNY 35,556,632.88, showing a significant increase of 1,895.59% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 24,947,495.90, up by 364.32% year-on-year[5] - Basic earnings per share reached CNY 0.04, reflecting a substantial increase of 566.67%[5] - Operating profit for Q1 2022 was RMB 38.79 million, significantly up from RMB 4.36 million in the same period last year[17] - Net profit for Q1 2022 was RMB 31.98 million, compared to a net loss of RMB 2.06 million in Q1 2021, marking a turnaround[17] - The total revenue for Q1 2022 reached RMB 387.75 million, an increase of 16.9% compared to RMB 330.70 million in Q1 2021[16] - The total comprehensive income for Q1 2022 was approximately ¥31.98 million, a decrease from ¥34.08 million in Q1 2021[22] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 23,905,233.68, an increase of 43.30% compared to the previous year[5] - The net cash flow from operating activities for Q1 2022 was ¥23.91 million, a significant improvement compared to a net outflow of ¥59.95 million in Q1 2021[21] - The net cash flow from investing activities for Q1 2022 was a negative ¥40.46 million, an improvement from a negative ¥300.96 million in Q1 2021[21] - The net cash flow from financing activities for Q1 2022 was a negative ¥3.25 million, compared to a positive ¥326.17 million in Q1 2021[22] - Current liabilities decreased to RMB 1.46 billion from RMB 1.64 billion at the end of 2021, reflecting improved liquidity[14] Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,371,611,642.05, a decrease of 1.83% from the end of the previous year[6] - Total assets as of March 31, 2022, were RMB 6.37 billion, a decrease from RMB 6.49 billion at the end of 2021[15] - The total liabilities decreased to RMB 3.04 billion from RMB 3.19 billion at the end of 2021, indicating a reduction in financial leverage[15] - The equity attributable to shareholders increased to RMB 2.93 billion from RMB 2.89 billion at the end of 2021, reflecting a strengthening balance sheet[15] Shareholder Information - The company reported a total of 26,046 common shareholders at the end of the reporting period[10] Non-Recurring Gains - Non-recurring gains totaled CNY 10,609,136.98, with significant contributions from asset disposals and government subsidies[7] Research and Development - Research and development expenses for Q1 2022 were RMB 6.77 million, down from RMB 8.05 million in Q1 2021, suggesting a focus on cost management[17] Sales and Revenue - The increase in net profit was primarily driven by higher profit margins on biochemical products and increased sales revenue[8] - The company received cash from sales of goods and services amounting to approximately ¥529.40 million in Q1 2022, compared to ¥485.41 million in Q1 2021[20] - Inventory increased to RMB 152.36 million, up from RMB 111.70 million at the end of 2021, indicating potential growth in sales[14] Investment Income - The company reported an investment income of RMB 16.68 million in Q1 2022, a significant increase from RMB 0.03 million in Q1 2021[17] Return on Equity - The return on equity (ROE) increased to 1.23%, up by 1.13 percentage points from the previous year[6] Cash and Cash Equivalents - The cash and cash equivalents at the end of Q1 2022 were approximately ¥838.75 million, a decrease from ¥858.54 million at the beginning of the quarter[22] Tax Refunds - The company reported a decrease in cash received from tax refunds, totaling ¥3.56 million in Q1 2022, down from ¥5.26 million in Q1 2021[21]

Financial Performance - In 2021, the company achieved a net profit attributable to shareholders of the parent company amounting to ¥147,938,274.20, while the parent company realized a net profit of ¥4,191,034.11[6] - The company reported a total distributable profit of ¥200,207,320.93 at the end of 2021 after accounting for the legal surplus reserve and previous undistributed profits[6] - The company achieved an operating revenue of RMB 2.03 billion in 2021, representing a year-on-year increase of 7.55% compared to RMB 1.89 billion in 2020[23] - The net profit attributable to shareholders was RMB 147.94 million, a significant increase of 53.88% from RMB 96.14 million in the previous year[23] - The company reported a net cash flow from operating activities of RMB 368.65 million, up 13.99% from RMB 323.40 million in 2020[23] - The total assets increased to RMB 6.49 billion, reflecting a growth of 17.85% compared to RMB 5.51 billion at the end of 2020[23] - The company achieved a total revenue of 2,030.9 million RMB in 2021, representing a 7.55% increase compared to the previous year[79] - The gross profit margin improved to 22.93%, an increase of 5.99 percentage points compared to the previous year[85] Dividend and Profit Distribution - The proposed cash dividend for 2021 is ¥1.00 per 10 shares, totaling ¥86,658,576.60 to be distributed to shareholders[6] - The company plans to carry forward the remaining undistributed profits to future years, with no capital reserve conversion or bonus shares proposed for this year[6] - The company has not proposed a cash profit distribution plan for the year, despite having positive distributable profits[193] - The company’s cash dividend policy stipulates that cumulative cash distributions over the last three years should not be less than 30% of the average annual distributable profits[193] Asset Restructuring - The company completed a significant asset restructuring by acquiring 100% equity of Haiyun Environmental Protection and 40% equity stakes in Shichuang Water, Shikang Water, and Green Movement Haiyun, with the transaction finalized in December 2021[9] - The company completed a major asset restructuring in 2021, acquiring 100% equity of Haiyun Environmental and 40% equity stakes in Shichuang Water, Shikang Water, and Green Dong Haiyun from Haining Water Group and Yunnan Water[99] - The company completed the transfer of equity and registration procedures for the major asset restructuring approved by the China Securities Regulatory Commission[148] Research and Development - The company completed one national invention patent and two provincial new product applications, receiving authorization for two invention patents, demonstrating its commitment to R&D[39] - Research and development expenses increased by 72.01% to 32.03 million RMB, primarily due to increased investments in subsidiaries[79] - The company has developed core patented technologies in wastewater treatment and solid waste disposal, enhancing its competitive edge[71] - The company completed the research and optimization of new pesticide formulations, including 5.0% Abamectin and 24% Imazalil, moving towards large-scale production[112] - The company is focusing on the development of environmentally friendly pesticide formulations to meet market demands and enhance product competitiveness[112] Market Expansion and Sales - The company achieved a new growth in sales revenue by optimizing sales assessment management and expanding into non-agricultural sectors such as landscaping and greening[38] - The company is actively promoting the use of plant growth regulators, which are characterized by low cost and high effectiveness, contributing to agricultural productivity[50] - The company is focusing on the development of green and efficient biopesticides, aligning with national agricultural modernization goals[49] - The company is leveraging innovation platforms and partnerships with research institutions to accelerate product structure adjustments and industry upgrades[77] - The company plans to expand its market presence and enhance its product offerings in the upcoming year[87] Operational Efficiency and Cost Management - The company has implemented measures to control raw material procurement costs amid rising prices, ensuring effective management of production costs[37] - The company has successfully reduced operational costs by 8% through efficiency improvements[173] - The company is actively responding to raw material price fluctuations by increasing the number of qualified suppliers and adjusting procurement cycles[139] - The company has established a strict supplier evaluation and assessment system, ensuring multiple qualified suppliers for key materials[67] Corporate Governance - The company has strengthened its corporate governance by revising 21 governance systems, enhancing operational standards and accountability[42] - The company has established a comprehensive governance structure, complying with relevant laws and regulations, and has improved internal control systems[163] - The internal control audit report issued by Tianjian Accounting Firm confirmed that the company maintained effective financial reporting internal controls as of December 31, 2021[200] - The company has implemented a risk prevention-oriented management approach, enhancing the effectiveness of internal control execution and management[198] Challenges and Risks - The company faced challenges such as rising raw material costs and energy consumption controls but continued to focus on market expansion and product innovation[36] - The company is facing risks related to rising raw material prices, which could impact production costs and profitability[155] - The company faces increased environmental protection costs due to stricter regulations, which may impact financial performance[157] - The competitive landscape in the environmental services industry is intensifying, with larger firms leveraging capital advantages, potentially increasing pressure on smaller competitors[158] Employee Development - The total number of employees in the parent company and major subsidiaries is 1,532, with 425 in the parent company and 1,107 in subsidiaries[188] - The company conducted 414 external training sessions and over 4,280 internal training sessions in 2021 to enhance employee skills and safety awareness[191] - The company has established a vocational skills evaluation system to assess employee skills and reward high-performing employees monthly[191] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[173] - New product launches are expected to contribute an additional 300 million in revenue in the upcoming year[174] - The company aims to achieve a revenue target of 2.1 billion yuan in 2022, although this does not constitute a profit forecast or commitment to investors[154]

浙江钱江生物化学股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2021 年第三季度报告 证券代码：600796 证券简称：钱江生化 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 动幅度(%) | | 增减变动幅度 | | | | | | (%) | | 营业收入 | 106,752,654.47 | 23.70 | 365,402,544.39 | 31. ...

2021 年半年度报告 公司代码：600796 公司简称：钱江生化 浙江钱江生物化学股份有限公司 2021 年半年度报告 1 / 157 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人叶启东、主管会计工作负责人沈建浩及会计机构负责人（会计主管人员）沈建浩 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承诺，敬 请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司存在的风险因素已在本报告中详细描述，敬请查 ...

2020 年年度报告 公司代码：600796 公司简称：钱江生化 浙江钱江生物化学股份有限公司 2020 年年度报告 1 / 198 2020 年年度报告 重要提示 四、 公司负责人叶启东、主管会计工作负责人沈建浩及会计机构负责人（会计主管人员）沈 建浩声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 2021 年 4 月 19 日,公司召开九届五次董事会，审议通过了《公司 2020 年度利润分配预案》。 经天健会计师事务所（特殊普通合伙）审计，公司 2020 年度合并报表实现的归属于母公司 股东的净利润 5,136,504.05 元，母公司实现净利润 47,198,360.31 元，根据《公司章程》有关规 定，2020 年度母公司实现净利润提取 10%的法定盈余公积 4,719,836.03 元，加年初未分配利润 153,956,865.95 元，扣除上年度分配现金红利 0 元，2020 年末母公司可供股东分配的利润为 196,435,390.23 元。 根据公司分红政策和经营情况，提出 2020 年度利润分配预案：本年度不进行利润分配，也不 进行 ...

2020 年年度报告 2020 年年度报告 公司代码：600796 公司简称：钱江生化 浙江钱江生物化学股份有限公司 2020 年年度报告 1 / 198 根据公司分红政策和经营情况，提出 2020 年度利润分配预案：本年度不进行利润分配，也不 进行资本公积金转增股本。 未分配利润主要用于补充公司日常生产经营的流动资金。 六、 前瞻性陈述的风险声明 重要提示 四、 公司负责人叶启东、主管会计工作负责人沈建浩及会计机构负责人（会计主管人员）沈 建浩声明：保证年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 2021 年 4 月 19 日,公司召开九届五次董事会，审议通过了《公司 2020 年度利润分配预案》。 经天健会计师事务所（特殊普通合伙）审计，公司 2020 年度合并报表实现的归属于母公司 股东的净利润 5,136,504.05 元，母公司实现净利润 47,198,360.31 元，根据《公司章程》有关规 定，2020 年度母公司实现净利润提取 10%的法定盈余公积 4,719,836.03 元，加年初未分配利润 153,956,865.95 元，扣除上年 ...

2021 年第一季度报告 公司代码：600796 公司简称：钱江生化 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 3 / 19 本报告期末 上年度末 本报告期末比上年度末 增减(%) 总资产 1,131,028,548.73 1,160,355,218.33 -2.53 归属于上市公司股东 的净资产 595,184,465.10 601,201,431.55 -1.00 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) 经营活动产生的现金 流量净额 23,290,923.88 -16,395,979.06 不适用 年初至报告期末 上年初至上年报告期末 比上年同期增减（%） 营业收入 118,248,766.83 77,458,567.05 52.66 归属于上市公司股东 的净利润 -5,986,641.20 -4,554,649.27 不适用 归属于上市公司股东 的扣除非经常性损益 的净利润 -9,438, ...